Citigroup Maintains Buy on Beam Therapeutics, Lowers Price Target to $60

Benzinga · 05/11/2023 05:24
Citigroup analyst Samantha Semenkow maintains Beam Therapeutics (NASDAQ:BEAM) with a Buy and lowers the price target from $62 to $60.